However, clinical immunotherapy outcomes show that many monoclonal antibodies have poor clinical efficacy in advanced colorectal cancer, although anti-PD-1 and anti-PD-L1 monoclonal antibodies have obvious efficacy in the treatment of metastatic colorectal cancer [14–17]. The gene discussed is CD274; the disease is colorectal cancer.